Gardasil again denied approval for women 27-45

By Lewis Krauskopf and Ransdell Pierson

NEW YORK (Reuters) - U.S. health regulators have again withheld approval for the use of Merck & Co Inc’s Gardasil cervical cancer vaccine by women aged 27 to 45, asking for longer-term clinical data, the drugmaker said on Friday.

The U.S. Food and Drug Administration recommended Merck submit data when a 48-month study on a test group has been completed. The agency also withheld approval in June on Merck’s initial application that was based on data collected through an average of 24 months.

Merck shares fell nearly 3 percent in midday trading.

Gardasil, one of Merck’s most successful newer products, was approved in 2006 for preventing cervical cancer and genital warts in females between the ages of 9 and 26.

It works by preventing infection with the sexually transmitted human papillomavirus (HPV), which causes cervical cancer.

“Gardasil’s efficacy drops sharply once females have been exposed to HPV and this is probably the genesis of the problem with the older female population that Merck has been pushing for in this new application,” Sanford Bernstein analyst Tim Anderson said in a research note.

Moreover, because effectiveness is naturally lower in older females, Merck could have difficulty convincing insurers to cover Gardasil in that group should it be approved for them, Anderson added.

The FDA letter does not affect the use of the drug in the approved age group, or Merck’s recently filed application to expand use to males, the company said. By preventing infection among males, the hope is they would not be able to spread the virus to females through sexual contact.

Anderson expressed uncertainty about the FDA’s eventual decision on Gardasil’s use in males and about its sales potential in that population.

Merck on Friday also stood by its 2009 sales and earnings targets. It said it would update other elements of its forecast in a February 3 earnings conference call. In December, the company forecast Gardasil sales of $1.4 billion to $1.6 billion for 2009.

Global sales of the vaccine fell 4 percent to $401 million in the third quarter. Many girls and women in the approved age group have already taken the vaccine and it is now facing competition overseas from GlaxoSmithKline Plc’s Cervarix.

Merck shares were down 79 cents to $28.57 in midday trading on the New York Stock Exchange.

(Reporting by Lewis Krauskopf and Ransdell Pierson, editing by John Wallace and Andre Grenon)


Related Posts:

NEW YORK (Reuters) - U.S. health regulators want longer-term data on the use of Merck & Co’s Gardasil cervical cancer vaccine in an older group of women before they will approve the vaccine for those women, the drugmaker said on Friday. The U.S. Food and Drug Administration has issued a second complete response letter to Merck

Full Post: More data sought for Merck’s Gardasil in older women

LONDON (Reuters) - A study of Merck & Co Inc’s cervical cancer vaccine Gardasil found that allergic reactions were uncommon and most young women can tolerate subsequent doses, Australian researchers said on Wednesday. The research involved 25 Australian girls with suspected hypersensitivity to the vaccine which was administered as part of a national immunization program to

Full Post: Allergic reactions to Gardasil uncommon: study

By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - A vaccine designed to protect women and girls from cervical cancer caused by a wart virus may protect men, too, maker Merck and Co reported on Thursday. The Gardasil vaccine was 90 percent effective in preventing lesions, mostly sexually transmitted warts, caused by the virus in men,

Full Post: Merck vaccine protects men from wart virus, too

By Will Dunham WASHINGTON (Reuters) - A quarter of girls aged 13-17 in the United States received Merck & Co’s Gardasil vaccine last year to protect against the human papillomavirus, which causes cervical cancer, the U.S. government said on Thursday. A report by the Centers for Disease Control and Prevention provided the first look at how many

Full Post: Quarter of adolescent U.S. girls received HPV vaccine

By Ransdell Pierson NEW YORK (Reuters) - U.S. regulators on Tuesday said their review of clinical trials does not suggest Merck & Co’s Singulair asthma drug or similar medicines cause suicide or suicidal thought, although the data were inadequate to draw a firm conclusion. However, the U.S. Food and Drug Administration said it was continuing to review

Full Post: FDA says Singulair data do not suggest suicide link

Site Navigation

Most Read